Novavax (NVAX) Gross Profit Growth (3y) (2014 - 2026)
Powered by 
Analysis
Novavax (NVAX) Gross Profit Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 9.20% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 10.09% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 77.42% |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 28.75% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 45.27% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 59.77% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 80.79% |
| 10 | Novavax | 1.67 Bn | 948.56 Mn | 42.45 Mn | -51.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -51.35% |
| Mar 31, 2026 | 32.42% |
| Dec 31, 2025 | -10.71% |
| Sep 30, 2025 | -45.36% |
| Jun 30, 2025 | 66.67% |
| Mar 31, 2025 | -1.78% |
| Dec 31, 2024 | -38.52% |
| Sep 30, 2024 | -48.88% |
| Jun 30, 2024 | 7.40% |
| Mar 31, 2024 | -57.37% |
| Sep 30, 2015 | 25.16% |
| Jun 30, 2015 | 78.60% |
| Mar 31, 2015 | 105.40% |
| Jun 30, 2014 | 21.27% |
| Mar 31, 2014 | 108.35% |